
HSJ633: The Peptide That Could Revolutionize Preterm Birth Prevention
A groundbreaking 2025 study introduces HSJ633, a first-of-its-kind IL-6 receptor peptide that prevents inflammation-induced preterm birth by selectively blocking STAT3 signaling while preserving fetal-safe pathways. This precision therapy could revolutionize maternal-fetal medicine and reduce neonatal complications worldwide.






